| Autor: |
de Kemp, E. C. M., Moleman, P., Hoogduin, C. A. L., Broekman, T. G., Goedhart, A., Schaap, C. P. D. R., van den Berg, P. C. |
| Předmět: |
|
| Zdroj: |
Psychopharmacology; 2002, Vol. 160 Issue 1, p67, 7p, 2 Charts, 3 Graphs |
| Abstrakt: |
Abstract Rationale: Co-morbidity of mood and anxiety disorders is often ignored in pharmacotreatment outcome studies and this complicates the interpretation of treat-ment response. The clinical trials are usually based on single categories from the Diagnostic and Statistical Manual of Mental Disorders (DSM). Objectives: The present study is a first attempt to differentiate the re-sponses to antidepressants using a design that differs from that used in previous clinical trials. To avoid bias due to co-morbidity, we included patients with any DSM-III- R diagnosis of mood or anxiety disorder for which an-tidepressant treatment was indicated. We also explored the role of the diagnosis at the first episode in the efficacy of the different antidepressants. Methods: A total of 92 outpatients with a mood and/or anxiety disorder were ran-domly assigned to treatment with imipramine or fluvox-amine in a 6-week study. The diagnosis at the first epi-sode--or primary diagnosis--was available for 78 pa-tients, 40 with a primary depression and 38 with a prima-ry anxiety disorder. Results: Analyses using the MIXED procedure for repeated measures showed no general dif-ferences between treatment with imipramine and... [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
